< Back to previous page
Project
Exploring the therapeutic effect of Akt2/PKB- Beta –neutralising nanobodies in cancer cells
Akt2, has recently gained in importance as a therapeutic target. Although a lot of effort is being put into the development of Akt2-specific inhibitors, to date, no such inhibitor is available. Our group has obtained an Akt2-specific nanobody that triggers mitophagy in breast cancer cells. It is our objective to further characterize this nanobody and determine its therapeutic effect.
Date:1 Jan 2016 → 31 Dec 2019
Keywords:Akt2/PKB- Beta, Nanobody technology, cancer
Disciplines:Medical biochemistry and metabolism, Biochemistry and metabolism, Systems biology